Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Leukemia, Myeloid, Acute 9Myelodysplastic Syndromes 5Myeloproliferative Disorders 3Myelodysplastic-Myeloproliferative Diseases 2Triple Negative Breast Neoplasms 1Thrombocythemia, Essential 1Primary Myelofibrosis 1Polycythemia Vera 1Mesothelioma, Malignant 1Mesothelioma 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, B-Cell 1Leukemia, Myelomonocytic, Chronic 1Hodgkin Disease 1GATA2 Deficiency 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Filgrastim 13Cyclophosphamide 13Etoposide 12Doxorubicin 11fludarabine phosphate 10Vincristine 10Cyclosporine 10Peripheral Blood Stem Cell Transplantation 9Radiotherapy 8Prednisone 8Vinblastine 6Tacrolimus 6Rituximab 6Methotrexate 6Gemcitabine 6Bleomycin 6tanespimycin 5Vorinostat 5Ipilimumab 5Bortezomib 5temsirolimus 4Sirolimus 4Nivolumab 4Mycophenolic Acid 4Melphalan 4Magnetic Resonance Spectroscopy 4Ifosfamide 4Dacarbazine 4Cytarabine 4CTLA-4 Antigen 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Hodgkin Disease × decitabine and cedazuridine drug combination × Clear all
NCT05272384 2026-05-13

Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma

National Cancer Institute (NCI)

Phase 1 Recruiting
32 enrolled
Lymphoid

Hodgkin Disease, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡